Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
Actively Recruiting
Researchers are observing adults diagnosed with schizophrenia in the United States who have started treatment with xanomeline and trospium chloride KarXT. The study aims to describe real-world treatment patterns, effectiveness, and adverse events related to KarXT use in routine clinical care. Participants are those who have initiated KarXT treatment within 16 weeks with plans to discontinue prior antipsychotic treatments or are on stable antipsychotic regimens planning to switch to KarXT. The study follows these participants for up to 20 weeks to record treatment titration, switches, and continuation patterns. Concomitant psychiatric medications may continue at stable doses during the study. During the study, researchers collect data on adverse events, weight changes, clinical global improvement scores, schizophrenia-related relapses, treatment discontinuation reasons, and use of antiemetic treatments for gastrointestinal symptoms. Baseline information includes demographics, family history, diagnosis duration, and previous treatments. This observational study supports understanding KarXT treatment in real-world settings up to 20 weeks after initiation.
Actively Recruiting
Researchers are studying the effects and safety of SPN-812 viloxazine extended release in children aged 4 to 5 years who have Attention-DeficitHyperactivity Disorder ADHD. This study is a Phase 4, randomized, double-blind, placebo-controlled trial designed to compare SPN-812 with a placebo in preschool-age children diagnosed with ADHD. The goal is to evaluate how well the medication works and how tolerable it is in this young population. Participants will be randomly assigned to receive either 100mg SPN-812 or a placebo once daily for a 6-week treatment period. Before starting treatment, children will be screened for up to 4 weeks to determine eligibility. The total study duration for each participant is up to 10 weeks, including screening and treatment. This design allows researchers to compare the effects of SPN-812 against placebo over a set timeframe. During the study, participants will be evaluated using the ADHD Rating Scale, 4th Edition, Preschool Version ADHD-RS-IV-P to measure changes in ADHD symptoms. Other assessments include the Clinical Global Impression of Severity and Change scores. Parents or guardians will provide consent, and children will be regularly monitored for safety and treatment response. Researchers will collect data at baseline and at the end of the 6-week treatment period to assess the medications impact and any side effects.
Actively Recruiting
Researchers are conducting a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of solriamfetol in children aged 6 to under 12 years diagnosed with Attention Deficit Hyperactivity Disorder ADHD. The study aims to compare two different doses of solriamfetol against a placebo over a 6-week period. Participants will be randomly assigned to one of three groups solriamfetol dose A, solriamfetol dose B, or placebo. Each participant will take capsules once daily for up to 6 weeks. The study uses a parallel group design where participants receive only one of the study treatments. During the trial, children will be monitored regularly to assess changes in ADHD symptoms using the ADHD Rating Scale-5 ADHD-RS-5 total score from the start of the study to week 6. Safety and adherence to the study treatment will also be evaluated throughout the trial. The total participation duration is up to 6 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of solriamfetol in adolescents aged 12 to less than 18 years diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This Phase 3, multi-center, randomized, double-blind, placebo-controlled study lasts for 6 weeks and aims to compare two different doses of solriamfetol against a placebo. Participants will be randomly assigned to one of three groups solriamfetol dose A, solriamfetol dose B, or placebo. Each participant will take their assigned capsules once daily for up to 6 weeks. The study uses a parallel-group design, meaning each participant remains in their assigned group throughout the trial. During the trial, participants will be monitored regularly to assess changes in their ADHD symptoms using a standard rating scale. Safety and adherence to the study medication will be closely observed. The primary outcome measured is the change in the ADHD-RS-5 total score from the beginning of the study to week 6, reflecting the treatments effect on ADHD symptoms over the course of the trial.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled study to evaluate the treatment of irritability associated with Autism Spectrum Disorder ASD in pediatric patients aged 5 to 17 years. The diagnosis of ASD is confirmed using established diagnostic criteria and interviews. The study aims to assess the safety and effectiveness of lumateperone in reducing irritability symptoms in this population. Participants are randomly assigned to one of three groups a high dose of lumateperone, a low dose of lumateperone, or a placebo. The study includes a screening period of up to 14 days to confirm eligibility, followed by a 6-week double-blind treatment period during which the study drug or placebo is taken once daily. After treatment, there is a 1-week safety follow-up visit to monitor any effects after stopping the study drug. During the study, participants will attend visits for assessments including symptom rating scales like the Aberrant Behavior Checklist for irritability and Clinical Global Impression-Severity. Safety will be monitored throughout the trial and during follow-up visits. The total participation time covers screening, treatment, and safety monitoring, with specific evaluations at baseline and week 6 to measure changes in irritability.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.